(function(){var loadHandler=window['sl_{656BC694-C0A1-4D3A-883A-292145561588}'];loadHandler&&loadHandler(3, '<div id="spr0_3a3afe6"><div id="spr1_3a3afe6" class="kern slide"><img id="img1_3a3afe6" src="data/img5.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/><div id="svg6_3a3afe6" style="left:49.06px;top:94.123px;"><svg width="1182" height="3" viewBox="-1.333 -0.667 1182 3"><g fill="#c2b6ab" stroke="none"><path stroke="#c2b6ab" stroke-width="1.333" stroke-linecap="butt" transform="translate(-50.393677,-94.789497)" d="M50.394,95.456 H1229.606"/></g></svg></div><div id="svg9_3a3afe6" style="left:49.06px;top:94.123px;"><svg width="1182" height="3" viewBox="-1.333 -0.667 1182 3"><g fill="#cdd7dc" stroke="none"><path stroke="#cdd7dc" stroke-width="1.333" stroke-linecap="butt" transform="translate(-50.393677,-94.789497)" d="M50.394,95.456 H1229.606"/></g></svg></div></div><div id="spr2_3a3afe6" class="kern slide"><div id="spr3_3a3afe6" style="left:35.087px;top:58.784px;"><div style="width:0px;"><span id="txt0_3a3afe6" data-width="614.270874" style="top:-0.696px;">Personalised technology examples</span></div></div><div id="spr4_3a3afe6" style="left:1128.819px;top:682.205px;"><div style="width:0px;"><span id="txt1_3a3afe6" class="nokern" style="left:93.267px;top:0.686px;">4</span></div></div><div id="spr5_3a3afe6" style="left:60.632px;top:153.447px;"><div id="spr6_3a3afe6"><img id="img0_3a3afe6" src="data/img6.png" width="1146.949" height="507.26" alt=""/></div><div id="spr7_3a3afe6"><div style="width:0px;"><span id="txt2_3a3afe6" style="left:7.2px;top:-0.042px;">Â </span></div></div><div id="spr8_3a3afe6" style="left:106.903px;"><div style="width:0px;"><span id="txt3_3a3afe6" data-width="136.552094" style="left:-46.252px;top:-0.042px;">PM category</span></div></div><div id="spr9_3a3afe6" style="left:1222.657px;"><div style="width:0px;"><span id="txt4_3a3afe6" data-width="106.812500" style="left:-604.129px;top:-0.042px;">Examples</span></div></div><div id="spr10_3a3afe6" style="top:58.292px;"><div style="width:0px;"><span id="txt5_3a3afe6" style="left:7.2px;top:-29.188px;">1</span></div></div><div id="spr11_3a3afe6" style="left:106.903px;top:58.292px;"><div style="width:0px;"><span id="txt6_3a3afe6" data-width="126.625000" style="left:-46.252px;top:-28.163px;">Gene therapy</span></div><div style="width:0px;"><span id="txt7_3a3afe6" data-width="161.718750" style="left:-46.252px;top:-1.795px;">Targeted therapy</span></div></div><div id="spr12_3a3afe6" style="left:1222.657px;top:58.292px;"><div style="width:0px;"><span id="txt8_3a3afe6" data-width="87.645836" style="left:-604.129px;top:-28.163px;">Luxturna</span></div><div style="width:0px;"><span id="txt9_3a3afe6" data-width="234.927094" style="left:-604.129px;top:-1.795px;">Herceptin (trastuzumab)</span></div></div><div id="spr13_3a3afe6" style="top:177.998px;"><div style="width:0px;"><span id="txt10_3a3afe6" style="left:7.2px;top:-89.042px;">2</span></div></div><div id="spr14_3a3afe6" style="left:106.903px;top:177.998px;"><div style="width:0px;"><span id="txt11_3a3afe6" data-width="531.989624" style="left:-46.252px;top:-88.017px;">Test to identify likely (non-)responders to treatment and</span></div><div style="width:0px;"><span id="txt12_3a3afe6" data-width="285.260437" style="left:-46.252px;top:-61.648px;">subsequent therapeutic choice</span></div></div><div id="spr15_3a3afe6" style="left:1222.657px;top:177.998px;"><div style="width:0px;"><span id="txt13_3a3afe6" data-width="465.177094" style="left:-604.129px;top:-88.017px;">Larotrectinib/entrectinib for cancer patients with</span></div><div style="width:0px;"><span id="txt14_3a3afe6" data-width="491.593750" style="left:-604.129px;top:-61.648px;">NTRK gene fusions, sylfonylurea for MODY patients</span></div></div><div id="spr16_3a3afe6" style="top:396.569px;"><div style="width:0px;"><span id="txt15_3a3afe6" style="left:7.2px;top:-198.327px;">3</span></div></div><div id="spr17_3a3afe6" style="left:106.903px;top:396.569px;"><div style="width:0px;"><span id="txt16_3a3afe6" data-width="496.854187" style="left:-46.252px;top:-197.302px;">Test to identify patients who may experience adverse</span></div><div style="width:0px;"><span id="txt17_3a3afe6" data-width="466.854187" style="left:-46.252px;top:-170.934px;">drug reactions and subsequent therapeutic choice</span></div></div><div id="spr18_3a3afe6" style="left:1222.657px;top:396.569px;"><div style="width:0px;"><span id="txt18_3a3afe6" data-width="469.354187" style="left:-604.129px;top:-197.302px;">DPYD pharmacogenomic testing in oncology (and</span></div><div style="width:0px;"><span id="txt19_3a3afe6" data-width="453.802094" style="left:-604.129px;top:-170.934px;">subsequent changes in chemotherapy or dosing)</span></div></div><div id="spr19_3a3afe6" style="top:615.141px;"><div style="width:0px;"><span id="txt20_3a3afe6" style="left:7.2px;top:-307.613px;">4</span></div></div><div id="spr20_3a3afe6" style="left:106.903px;top:615.141px;"><div style="width:0px;"><span id="txt21_3a3afe6" data-width="476.135437" style="left:-46.252px;top:-306.588px;">Test to screen for disease or a genetic marker in an</span></div><div style="width:0px;"><span id="txt22_3a3afe6" data-width="507.177094" style="left:-46.252px;top:-279.195px;">asymptomatic population and subsequent therapeutic</span></div><div style="width:0px;"><span id="txt23_3a3afe6" data-width="59.854168" style="left:-46.252px;top:-252.826px;">choice</span></div></div><div id="spr21_3a3afe6" style="left:1222.657px;top:615.141px;"><div style="width:0px;"><span id="txt24_3a3afe6" data-width="436.083344" style="left:-604.129px;top:-306.588px;">BRCA screening and subsequent (omission of)</span></div><div style="width:0px;"><span id="txt25_3a3afe6" data-width="194.031250" style="left:-604.129px;top:-280.219px;">preventive measures</span></div></div><div id="spr22_3a3afe6" style="top:833.712px;"><div style="width:0px;"><span id="txt26_3a3afe6" style="left:7.2px;top:-416.899px;">5</span></div></div><div id="spr23_3a3afe6" style="left:106.903px;top:833.712px;"><div style="width:0px;"><span id="txt27_3a3afe6" data-width="498.572937" style="left:-46.252px;top:-415.874px;">Test to gain information about disease prognosis and</span></div><div style="width:0px;"><span id="txt28_3a3afe6" data-width="285.260437" style="left:-46.252px;top:-389.505px;">subsequent therapeutic choice</span></div></div><div id="spr24_3a3afe6" style="left:1222.657px;top:833.712px;"><div style="width:0px;"><span id="txt29_3a3afe6" data-width="492.541687" style="left:-604.129px;top:-415.874px;">OncotypeDX and subsequent (omission of) adjuvant</span></div><div style="width:0px;"><span id="txt30_3a3afe6" data-width="135.489594" style="left:-604.129px;top:-389.505px;">chemotherapy</span></div></div></div></div></div>', '{"s":[]}');})();